EcoDrugPlus

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSPFOG00000002503
Gene Symbol: BCR
3 Cross references
196 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSPFOG00000024771
Gene Symbol: BCR
1 Cross references
204 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSPFOG00000021924
Gene Symbol: BCR
1 Cross references
204 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSPFOG00000000615
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSPFOG00000020568
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSPFOG00000016829
Gene Symbol: CXCR2
3 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSPFOG00000010131
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSPFOG00000018011
Gene Symbol: LOC103140889
2 Cross references
389 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSPFOG00000014478
Gene Symbol: CFTR
1 Cross references
214 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSPFOG00000020219
Gene Symbol: LOC103138607
3 Cross references
198 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSPFOG00000005624
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSPFOG00000015574
Gene Symbol: LOC103147358
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).